Cumberland Pharmaceuticals Inc. (CPIX)
CPIX Stock Price Chart
Explore Cumberland Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze CPIX price movements and trends.
CPIX Company Profile
Discover essential business fundamentals and corporate details for Cumberland Pharmaceuticals Inc. (CPIX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
11 Aug 2009
Employees
91.00
Website
https://www.cumberlandpharma.comCEO
A. J. Kazimi
Description
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.
CPIX Financial Timeline
Browse a chronological timeline of Cumberland Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.13, while revenue estimate is $8.50m.
Dividend declared on 3 Aug 2026
A dividend of $1.50 per share was announced, adjusted to $1.50.
Earnings released on 5 May 2026
EPS came in at -$0.13 matching the estimated -$0.13, while revenue for the quarter reached $9.13m , beating expectations by +7.39%.
Earnings released on 3 Mar 2026
EPS came in at -$0.01 surpassing the estimated -$0.13 by +92.31%, while revenue for the quarter reached $13.68m , beating expectations by +60.87%.
Earnings released on 4 Nov 2025
EPS came in at -$0.06 surpassing the estimated -$0.13 by +53.85%, while revenue for the quarter reached $8.29m , missing expectations by -13.97%.
Earnings released on 5 Aug 2025
EPS came in at $0.02 , while revenue for the quarter reached $10.84m .
Earnings released on 6 May 2025
EPS came in at $0.16 surpassing the estimated -$0.01 by +1.70k%, while revenue for the quarter reached $11.71m , missing expectations by -3.84%.
Earnings released on 4 Mar 2025
EPS came in at -$0.02 surpassing the estimated -$0.11 by +81.82%, while revenue for the quarter reached $10.44m , beating expectations by +13.50%.
Earnings released on 7 Nov 2024
EPS came in at -$0.02 surpassing the estimated -$0.13 by +84.62%, while revenue for the quarter reached $9.09m , beating expectations by +6.01%.
Earnings released on 6 Aug 2024
EPS came in at $0.01 surpassing the estimated -$0.13 by +107.69%, while revenue for the quarter reached $9.85m , beating expectations by +15.83%.
Earnings released on 7 May 2024
EPS came in at -$0.05 falling short of the estimated $1.58 by -103.16%, while revenue for the quarter reached $8.50m , missing expectations by -34.69%.
Earnings released on 5 Mar 2024
EPS came in at -$0.11 falling short of the estimated $2.09 by -105.26%, while revenue for the quarter reached $9.35m , missing expectations by -61.72%.
Earnings released on 7 Nov 2023
EPS came in at $0.02 falling short of the estimated $1.39 by -98.56%, while revenue for the quarter reached $10.09m , missing expectations by -35.16%.
Earnings released on 8 Aug 2023
EPS came in at $0.16 falling short of the estimated $1.19 by -86.55%, while revenue for the quarter reached $10.89m , missing expectations by -0.62%.
Earnings released on 9 May 2023
EPS came in at $0.11 falling short of the estimated $1.43 by -92.31%, while revenue for the quarter reached $9.22m , missing expectations by -10.31%.
Earnings released on 7 Mar 2023
EPS came in at -$0.05 falling short of the estimated -$0.01 by -400.00%, while revenue for the quarter reached $9.12m , beating expectations by +13.01%.
Earnings released on 8 Nov 2022
EPS came in at $0.10 surpassing the estimated -$0.11 by +190.91%, while revenue for the quarter reached $11.41m , beating expectations by +41.37%.
Earnings released on 9 Aug 2022
EPS came in at -$0.09 surpassing the estimated -$0.13 by +30.77%, while revenue for the quarter reached $10.30m , beating expectations by +20.16%.
Earnings released on 10 May 2022
EPS came in at -$0.09 surpassing the estimated -$0.13 by +30.77%, while revenue for the quarter reached $11.18m , beating expectations by +21.60%.
Earnings released on 8 Mar 2022
EPS came in at -$0.26 falling short of the estimated -$0.01 by -2.50k%, while revenue for the quarter reached $8.32m , missing expectations by -31.70%.
Earnings released on 9 Nov 2021
EPS came in at -$0.02 surpassing the estimated -$0.11 by +81.82%, while revenue for the quarter reached $8.07m , missing expectations by -12.20%.
Earnings released on 10 Aug 2021
EPS came in at $0.08 surpassing the estimated -$0.07 by +214.29%, while revenue for the quarter reached $9.06m , beating expectations by +5.65%.
CPIX Stock Performance
Access detailed CPIX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
